News

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after 6 months of treatment in a retrospective chart review that included 102 patients with nAMD who had had suboptimal responses to other anti-VEGF therapies.

EssilorLuxottica’s Nuance Audio glasses, which are equipped with hearing aids, will be available over the counter in the US and Europe as soon as Q1 2025.

The data will be presented virtually at Angiogenesis, Exudation, and Degeneration 2025 on February 8 and February 10, 2025.

A qualitative study method illuminates patients’ fears for the future

Choroidal and retinal changes were examined with optical coherence tomography angiography

Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.

Real-world scenarios showcase a shift in treatment paradigms

From easing fears to improving mood, a recent study explores how music transforms the surgical experience for both patients and health care teams.

Intercontinental collaboration is key to unlocking ROP in our lifetime

Binocular eye tracking could serve as alternative to patching and provide visual acuity gains with heightened adherence rates

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

Previously, Susvimo was called the Port Delivery System with ranibizumab in the United States

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

Researchers reported identifying changes in 4 areas of the brain

Optical coherence tomography angiography (OCTA) was performed in all participants; the choroidal and retinal changes were examined and recorded.

The company states the acquisition will further MERIT’s service offerings, allowing for a seamless transition from preclinical to clinical phase of drug development.

The company offers year-round educational services on the conditions, using this month, in particular, to guide patients to needed resources.

The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA

OCU400 is the first gene therapy from the biotechnology company to move forward into Phase 3 with a broad retinitis pigmentosa (RP) indication

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated for treatment of AMD.

The company offers year-round educational services on the conditions, using this month in particular to guide patients to needed resources.

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated inherited retinal dystrophy achieved encouraging efficacious results.

Laru-zova is a gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa.

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections.